Sayegh, N., Swami, U. & Agarwal, N. Recent advances in the management of metastatic prostate cancer. JCO Oncol. Pract. 18, 45–55 (2022).

Article  PubMed  Google Scholar 

Kelly, W. K. et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. J. Clin. Oncol. 28 (Suppl. 18), LBA5411 (2010).

Google Scholar 

Kelly, W. K. et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J. Clin. Oncol. 30, 1534–1540 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Agarwal, N. et al. CONTACT-02: phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 42 (Suppl. 4), 18 (2024).

Google Scholar 

de Wit, R. et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N. Engl. J. Med. 381, 2506–2518 (2019).

Article  PubMed  Google Scholar 

Smith, M. et al. Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1. J. Clin. Oncol. 34, 3005–3013 (2016).

Article  CAS  PubMed  Google Scholar 

Sternberg, C. N. et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J. Clin. Oncol. 27, 5431–5438 (2009).

Article  CAS  PubMed  Google Scholar 

Agarwal, N. et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet 402, 291–303 (2023).

Article  CAS  PubMed  Google Scholar 

Chi, K. N. et al. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. Ann. Oncol. 34, 772–782 (2023).

Article  CAS  PubMed  Google Scholar 

Saad, F. et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 24, 1094–1108 (2023).

Article  CAS  PubMed  Google Scholar 

Madan, R. A., Karzai, F., VanderWeele, D. J., Cheng, H. H. & de Bono, J. S. Poly(ADP-ribose) polymerase inhibitor combinations in first-line metastatic castration-resistant prostate cancer: increasing toxicity with unclear benefits. J. Clin. Oncol. 41, 5501–5504 (2023).

Article  CAS  PubMed  Google Scholar 

Sartor, O. et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 385, 1091–1103 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sartor, O. et al. Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore) [abstract LBA13]. Ann. Oncol. 34 (Suppl. 2), 1254–1335 (2023).

Google Scholar 

Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502–1512 (2004).

Article  CAS  PubMed  Google Scholar 

Hussain, M. et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N. Engl. J. Med. 383, 2345–2357 (2020).

Article  CAS  PubMed  Google Scholar